PMID- 19018475
OWN - NLM
STAT- MEDLINE
DCOM- 20090430
LR  - 20231120
IS  - 0167-594X (Print)
IS  - 0167-594X (Linking)
VI  - 92
IP  - 1
DP  - 2009 Mar
TI  - A pilot study of everolimus and gefitinib in the treatment of recurrent 
      glioblastoma (GBM).
PG  - 99-105
LID - 10.1007/s11060-008-9741-z [doi]
AB  - Twenty-two patients with recurrent glioblastoma (GBM) were prospectively treated 
      with everolimus and gefitinib, designed to test the combined inhibition of 
      mammalian target of rapamycin (mTOR) and epidermal growth factor receptor (EGFR) 
      as part of a larger clinical trial. The primary endpoint was radiographic 
      response rate. Secondary endpoints included progression-free survival and 
      correlation of molecular profiles with treatment response. 36% of patients had 
      stable disease and 14% a partial response; however, responses were not durable 
      and only one patient was progression-free at six months. Radiographic changes 
      were not well characterized by conventional response criteria, and implied 
      differential effects of therapy within the tumor and/or antiangiogenic effects. 
      EGFR and PTEN status did not clearly predict response to treatment.
FAU - Kreisl, Teri N
AU  - Kreisl TN
AD  - Neuro-Oncology Branch, National Cancer Institute, 9030 Old Georgetown Road, 
      Bethesda, MD 20892, USA.
FAU - Lassman, Andrew B
AU  - Lassman AB
FAU - Mischel, Paul S
AU  - Mischel PS
FAU - Rosen, Neal
AU  - Rosen N
FAU - Scher, Howard I
AU  - Scher HI
FAU - Teruya-Feldstein, Julie
AU  - Teruya-Feldstein J
FAU - Shaffer, David
AU  - Shaffer D
FAU - Lis, Eric
AU  - Lis E
FAU - Abrey, Lauren E
AU  - Abrey LE
LA  - eng
PT  - Clinical Trial, Phase I
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20081119
PL  - United States
TA  - J Neurooncol
JT  - Journal of neuro-oncology
JID - 8309335
RN  - 0 (Quinazolines)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
RN  - S65743JHBS (Gefitinib)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Brain Neoplasms/*drug therapy/metabolism/mortality
MH  - Disease-Free Survival
MH  - ErbB Receptors/biosynthesis
MH  - Everolimus
MH  - Female
MH  - Gefitinib
MH  - Glioblastoma/*drug therapy/metabolism/mortality
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local/*drug therapy
MH  - PTEN Phosphohydrolase/biosynthesis
MH  - Pilot Projects
MH  - Proto-Oncogene Proteins c-akt
MH  - Quinazolines/administration & dosage/adverse effects
MH  - Sirolimus/administration & dosage/adverse effects/analogs & derivatives
EDAT- 2008/11/20 09:00
MHDA- 2009/05/01 09:00
CRDT- 2008/11/20 09:00
PHST- 2008/09/29 00:00 [received]
PHST- 2008/11/10 00:00 [accepted]
PHST- 2008/11/20 09:00 [pubmed]
PHST- 2009/05/01 09:00 [medline]
PHST- 2008/11/20 09:00 [entrez]
AID - 10.1007/s11060-008-9741-z [doi]
PST - ppublish
SO  - J Neurooncol. 2009 Mar;92(1):99-105. doi: 10.1007/s11060-008-9741-z. Epub 2008 
      Nov 19.